Azael Freites‐Martinez

Azael Freites‐Martinez

Auto-generated profile, based on publicly available information

Azael Freites‐Martinez

Department of Dermatology, Hospital Ruber de Juan Bravo Universidad Europea Madrid Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
AFA. Freites-Martinez
A. Freites-Martinez
NSN. Santana
N. Santana
SAS. Arias-Santiago
S. Arias-Santiago
AVA. Viera
A. Viera

18 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
PSPietro Sollena
Pietro Sollena
VNVasiliki A. Nikolaou
Vasiliki A. Nikolaou
ELIAS KOTTEASELIAS KOTTEAS
ELIAS KOTTEAS
ASAlexandros Stratigos
Alexandros Stratigos
DFDavide Fattore
Davide Fattore
OPOn Behalf Of The Eadv Task Force “Dermatology For Cancer Patients”
On Behalf Of The Eadv Task Force “Dermatology For Cancer Patients”
Background: The introduction of cyclin-dependent kinase inhibitors (CDK4/6i) was a great advance in therapeutics for patients with estrogen receptor+/human epidermal growth factor receptor (HER2) locally advanced and metastatic breast cancer. Despite the increasing use of these agents, their adverse drug-related events have not yet been fully characterized. We describe the spectrum of cutaneous adverse reactions occurring in advanced breast cancer patients treated with cyclin-dependent kinase inhibitors, analyzing types, severity, time to onset, and possible treatment outcomes. Methods: We performed a multicentric retrospective study including patients with advanced breast cancer who developed cutaneous lesions during treatment with CDK4/6i in the period from June 2020 to June 2021. Patients > 18 years were recruited at eleven onco-dermatology units located in Albania (1), Argentina (1), France (1), Greece (3), Italy (3), and Spain (2). We evaluated patients’ epidemiological and clinical characteristics, types of cutaneous adverse events, their time to onset, and treatment outcomes. The severity of the skin reactions was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 score. Results: Seventy-nine patients (median age: 62.3 years; range 39–83 years) were included in the study, and, collectively, we recorded a total of 165 cutaneous adverse events during follow-up visits. The most frequent cutaneous reactions were pruritus (49/79 patients), alopecia (25/79), and eczematous lesions (24/79). Cutaneous toxicities were usually mild in severity (>65%) and occurred after a median of 6.5 months. Only four patients (5%) required treatment discontinuation due to the severity of the skin lesions. The majority of the skin reactions were managed with topical treatments. Conclusions: To the best of our knowledge, we present the largest case series of cutaneous adverse events developing in advanced breast cancer patients treated with CDK4/6i. We showed that cutaneous toxicities are usually mild in severity, and manageable with standard supportive care; however, in selected cases, they can lead to treatment discontinuation with possible implications for patients’ clinical outcomes.
1

30 October 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
DFDavide Fattore
Davide Fattore
ZAZoe Apalla
Zoe Apalla
AFAzael Freites‐Martinez
Azael Freites‐Martinez
NTNello Tommasino
Nello Tommasino
VNVasiliki A. Nikolaou
Vasiliki A. Nikolaou
VSVincent Sibaud
Vincent Sibaud

1 June 2015 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
PDF file
AFAzael Freites-Martinez
Azael Freites-Martinez
AMAmalia Moreno-Torres
Amalia Moreno-Torres
ANAlmudena Hernández Núñez
Almudena Hernández Núñez
DMDiego Martinez-Sanchez
Diego Martinez-Sanchez
MHMaria Huerta-Brogeras
Maria Huerta-Brogeras
JBJesus Borbujo
Jesus Borbujo
We report the case of a 35-year-old woman with deep-red asymptomatic macules on the plantar and dorsal skin of the right great toe. Histopathologic fi ndings were compatible with Angioma serpiginosum. Immunohistochemical stains for estrogens and progesterone receptors were negative. Dermoscopy showed an erythematous parallel ridge pattern with double rows of irregular dots and globules. We report an unusual case of angioma serpiginosum with acral volar skin involvement. The dermoscopic features described may aid in the diagnosis of AS in this specifi c skin area. Acral volar skin involvement must be included in the clinical spectrum of Angioma serpiginosum and in the differential diagnosis of acral vascular lesions.

26 October 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
ZAZoe Apalla
Zoe Apalla
AFA. Freites‐Martinez
A. Freites‐Martinez
KGKaterina Grafanaki
Katerina Grafanaki
AOA. Ortiz‐Brugues
A. Ortiz‐Brugues
VNVasiliki A. Nikolaou
Vasiliki A. Nikolaou
VSV. Sibaud
V. Sibaud
Background: There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists.Objective: To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus.Methods: The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force ‘Dermatology for Cancer Patients’ who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia. The questionnaire consisted of 84 statements in total, regarding diagnosis and treatment of EGFRi‐induced acneiform rash. Experts responded to an anonymous 5‐point Likert scale survey. The coordinators collected the first‐round responses that were checked for consensus (≥75% agreement in positive [agree or strongly agree] or in negative [disagree or strongly disagree] vote). The statements that did not reach strong consensus in the first round were revised, according to experts' feedback, for a second‐round survey.Results: Strong consensus was reached in 75/84 (89.3%) of the statements, whilst moderate consensus was achieved in 6/84 elements. Key points include consideration of low‐dose isotretinoin for refractory grade II/III acneiform rash, use of topical steroid‐sparing agents like topical pimecrolimus in the maintenance phase and use of doxycycline in either 100 or 200 mg per day as prophylactic treatment. Interestingly, experts did not recommend topical antibiotics, neither for prevention, nor for treatment. Consensus failure in 3/84 objects is mostly related to the lack of robust data on these topics.Conclusion: This consensus offers crucial insights often overlooked by radiotherapists, general practitioners, dermatologists and oncologists, and it is expected to improve the management of oncologic patients treated with EGFRi in different settings and continents.
1

11 July 2023 in JAAD International
Verified
Journal Article
Open access
ACAndrea Catalan-Griffiths
Andrea Catalan-Griffiths
PPPaola Pasquali
Paola Pasquali
SASalvador Arias-Santiago
Salvador Arias-Santiago
PVPedro Valeron
Pedro Valeron
AMAntonio Martinez-Lopez
Antonio Martinez-Lopez
AFAzael Freites-Martinez
Azael Freites-Martinez
Many therapies are available to treat low-risk superficial basal cell carcinoma (lr-sBCC), which may complicate the shared decision-making (SDM) process. To assess the SDM process of patients and physicians when deciding lr-sBCC therapy as well as the factors that may influence the SDM process. A prospective, multicenter cohort study was conducted over 18 months, from October 2018 to April 2020, in 3 tertiary university hospitals and 1 private hospital. This study included 107 patients. There was a weak positive correlation between Shared Decision-Making Questionnaire-Patient version (SDM-Q-9) and Shared Decision-Making Questionnaire-Physician version (SDM-Q-Doc) (Spearman’s correlation coefficient [rs] [105] = 0.21; P = .03). Most patients (71%) chose a nonsurgical treatment after the SDM process. Patients with higher satisfaction with the SDM had lower decisional conflict and decisional regret (P < .001). Patients aged >80 years had higher rates of significant decisional conflict. When evaluating treatment decisions, the highest median score for decisional conflict (22, IQR [16]; P = .01) was observed among patients who chose a surgical excision. Patients may have self-selected to participate. This study suggests that some patients may prefer less invasive therapies for lr-sBCC. The SDM process may reduce decisional conflict and decisional regret.